Human Papillomavirus Quadrivalent Vaccine Brand Name– Gardasil
What is Human Papillomavirus Quadrivalent Vaccine
Human papillomavirus quadrivalent vaccine (Gardasil quadrivalent) is a recombinant vaccine indicated for the prevention of human papillomavirus (HPV) infections and the diseases associated with these infections.
The vaccine is only effective against the 4 HPV types contained within the vaccine, which include HPV types 6, 11, 16, and 18.
The other commercially available HPV vaccine, Gardasil 9, is effective against HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58. HPV vaccines are only prophylactic and will not treat an active HPV infection.
Therefore, to offer the greatest protection, it is recommended to administer the vaccine prior to exposure (i.e., before onset of sexual activity).
Patients with previous exposure to HPV may still achieve benefit from the vaccine; however, no clear evidence of protection from disease caused by HPV types for which patients are PCR positive or seropositive at baseline exists.
The duration of protection has not been clearly defined; however, data indicate no loss of protection from HPV vaccines after 8 to 10 years.
Human papillomavirus quadrivalent vaccine is FDA-approved for use in both females and males ages 9 to 26 years.
- human papillomavirus (HPV) infection prophylaxis
- abdominal pain
- acute disseminated encephalomyelitis
- anaphylactic shock
- anaphylactoid reactions
- dental pain
- diabetes mellitus
- erythema nodosum
- Guillain-Barre syndrome
- hemolytic anemia
- injection site reaction
- lupus-like symptoms
- muscle paralysis
- nasal congestion
- optic neuritis
- pulmonary embolism
- skin hypopigmentation
- Stevens-Johnson syndrome
- pap smear
- pelvic exam
- anticoagulant therapy
- human immunodeficiency virus (HIV) infection
- neoplastic disease
- radiation therapy
- severe combined immunodeficiency (SCID)
- vitamin K deficiency
- yeast hypersensitivity